SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 2168703

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 2168703

BK virus (BKV) Infection - Epidemiology Forecast - 2036

PUBLISHED:
PAGES: 114 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 3990
PDF & Excel (2-3 User License)
USD 4988
PDF & Excel (Site License)
USD 6982
PDF & Excel (Global License)
USD 8977

Add to Cart

BK virus infection Insights and Trends

  • The BKV disease funnel is substantially larger at the viremia stage than at overt disease: In the US, approximately 25% of kidney transplant recipients develop BKV viremia, with a substantial proportion progressing to BKVAN. Using a 40% viremia-to-BKVAN progression rate, the epidemiologic funnel translates into a sizeable BKVAN population, underscoring why kidney transplantation represents the major reservoir of clinically relevant BKV disease.
  • Although BKPyV is also clinically relevant in hematopoietic stem cell transplantation (HSCT), particularly in BKPyV-associated hemorrhagic cystitis, the most mature epidemiological and therapeutic evidence base remains concentrated in kidney transplantation.
  • The viremia-to-BKVAN conversion is highly heterogeneous across the 7MM, reflecting differences in transplant populations, immunosuppressive regimens, screening frequency, viral-load thresholds, and diagnostic practices.
  • The diagnosed prevalent cases of BKHC in the US are estimated at approximately 1,275 cases in 2025, representing the largest patient share across the 7MM, driven by the substantial volume of HSCT procedures and the resulting susceptibility to BK virus reactivation and hemorrhagic cystitis among transplant recipients.
  • Among classification-specific BKVAN cases in kidney transplant recipients across EU4 and the UK, Class 2 represented the largest segment in 2025, with ~500 cases, followed by Class 1 at ~300 cases and Class 3 at ~95 cases. This distribution highlights Class 2 as the predominant histopathological grade within the diagnosed BKVAN population in the region.
  • Across EU4 and the UK, autologous HSCT cases consistently outnumbered allogeneic HSCT cases, totaling ~15,500 versus ~12,500 in 2025, respectively. The higher volume of autologous HSCT reflects its broader utilization across hematologic malignancies, particularly multiple myeloma and lymphoma, whereas allogeneic HSCT is primarily used in selected patients with hematologic malignancies requiring donor-derived hematopoietic reconstitution.
  • Reported BKPyV rates vary according to transplant population, immunosuppressive regimen, screening frequency, assay methodology, viral-load thresholds, and definitions of DNAemia versus nephropathy. The 2024 consensus guidelines specifically identify the need for improved international standards, better characterization of viral genotypes and variants, and optimization of screening intervals.
  • In Japan, Grade 2 emerged as the leading severity level for HSCT-associated BKHC cases, accounting for ~405 cases in 2025, followed by Grade 3 at ~295 cases, while Grade 1 and Grade 4 remained equal at ~110 cases each.
  • The diagnosed prevalent cases of BKV infection in the US are estimated at ~4,300 cases in 2025, representing the largest patient share among the 7MM. The higher diagnosed burden in the US may reflect its large transplant population, greater availability of routine BKV PCR-based surveillance, and broader recognition of BKV infection in immunocompromised patients, particularly kidney transplant recipients.

DelveInsight's 'BK Virus Infection - Epidemiology Forecast - 2036' report delivers an in-depth understanding of BK virus infection, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered:

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

BK Virus Infection Understanding

BK Virus Infection Overview and Diagnosis

BK virus (BKPyV), also known as a human polyomavirus, is a common virus that is typically acquired during childhood. Primary infection is usually asymptomatic or causes mild cold-like symptoms. After the initial infection, the virus remains latent for life in the kidneys and the epithelial lining of the ureters and urinary bladder. In healthy individuals, the immune system generally keeps the virus in a dormant state. However, when immune function is suppressed, BKV may reactivate and cause clinically significant infection. Reactivation occurs most commonly in kidney transplant recipients, who require long-term immunosuppressive therapy to prevent graft rejection. Active BKV infection can involve the kidneys, ureters, and bladder and may lead to renal injury.

The diagnosis of BKV infection relies on a combination of complementary laboratory and histopathological techniques, selected based on the clinical setting, the urgency of evaluation, and the available diagnostic infrastructure. Initial assessment typically includes quantitative polymerase chain reaction (PCR) testing for BK viral DNA in urine and plasma, with viruria serving as an early marker of viral reactivation and persistent viremia indicating an increased risk of BKVAN.

BK virus infection Epidemiology

Key Findings from BK virus infection Epidemiological Analysis and Forecast

  • The total number of BKVAN cases across the 7MM is expected to increase from approximately ~4000 cases in 2025, primarily reflecting the growing kidney transplant population, continued exposure to immunosuppressive therapy, and improved screening and surveillance for BKPyV DNAemia among kidney transplant recipients.
  • Among BKVAN cases in US kidney transplant recipients, Class 2 represented the largest classification-specific segment, totaling ~1,650 cases in 2025.
  • According to epidemiological analysis, BKVAN cases in kidney transplant recipients across EU4 and the UK totaled ~900 in 2025. Among these countries, France recorded the highest number of cases at ~350, followed by Italy at ~200 and the UK at ~170, while Germany reported the lowest count at ~35 cases.
  • In Japan, allogeneic HSCT cases consistently outnumbered autologous HSCT cases, totaling ~3,750 versus ~2,100 in 2025.
  • Among classification-specific BKVAN cases in kidney transplant recipients across EU4 and the UK, Class 2 represented the largest segment in 2025, with ~500 cases, followed by Class 1 at ~300 cases and Class 3 at ~95 cases. This distribution highlights Class 2 as the predominant histopathological grade within the diagnosed BKVAN population in the region.

Industry Experts and Physician Views for BK Virus Infection

To keep up with BK virus infection dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the BK virus infection epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 20+ KOLs to gather insights at country level. Centers such as the University of Santo Tomas, Berlin Institute of Health at Charite, Paris-Est Creteil University, UCL Queen Square Institute of Neurology etc. were contacted.

Their opinion helps understand, validate, highlight and provide epidemiological context in BK virus infection.

Scope of the Report:

  • The report covers a segment of an executive summary, a descriptive overview of BK virus infection, explaining their causes, signs and symptoms and pathogenesis.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
  • The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
  • A detailed review of current challenges in establishing the diagnosis.

Report Insights

  • BK Virus Infection Patient Population Forecast
  • Country-wise Epidemiology Distribution
  • Total Cases of BK Viremia in Kidney Transplant Patients
  • Total Cases of BKVAN
  • Classification-specific Cases of BKVAN
  • Type-specific HSCT Cases
  • Total Cases of BKHC
  • Grade-specific Cases of BKHC

Report Key Strengths

  • Epidemiology-based (Epi-based) Bottom-up Forecasting
  • 11-year forecast
  • Patient Burden Trends (by geography)
  • The 7MM Coverage

FAQs:

Epidemiology Insights

  • What is the forecast period covered in the report?
  • How is epidemiological data collected and analyzed for forecasting purposes?
  • Out of all EU4 countries and the UK, which country had the highest population of BK virus infection cases?
  • What are the disease risks and burdens of BK virus infection?
  • At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
  • What would be the forecasted patient population of BK virus infection at the 7MM level?

Reasons to Buy:

  • The report will help in developing business strategies by understanding the latest epidemiology trends.
  • Insights on patient burden/ prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand KOLs' perspectives on the dynamic epidemiology trends.
  • This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.
Product Code: DIEI0498

Table of Contents

1. Key Insights

2. Report Introduction

3. BK Virus Infection Epidemiology Overview at a Glance

  • 3.1. Patient Share (%) Distribution of BK Virus Infection in the 7MM in 2025
  • 3.2. Patient Share (%) Distribution of BK Virus Infection in the 7MM in 2036

4. Executive Summary

5. Disease Background and Overview

  • 5.1. Types of BKV Infection
  • 5.2. Causes and Risk Factors of BK Virus Infection
    • 5.2.1. Risk Factors
  • 5.3. Pathophysiology of BKV Infection
  • 5.4. Etiology of BKV Infection
  • 5.5. Diagnosis of BKV Infection
  • 5.6. Diagnostic Algorithm
    • 5.6.1. Differential Diagnosis
  • 5.7. Diagnostic Guidelines
    • 5.7.1. The Second International Consensus Guidelines on the Assessment of BK Polyomavirus in Kidney Transplantation, 2024
    • 5.7.2. American Society of Transplantation Infectious Diseases Community of Practice Clinical Transplantation, 2019
    • 5.7.3. Clinical Journal of American Society of Nephrology, 2018

6. Methodology of BK Virus Infection Epidemiology

7. Epidemiology and Patient Population

  • 7.1. Key Findings
  • 7.2. Assumptions and Rationale: 7MM
    • 7.2.1. United States
    • 7.2.2. EU4 and the UK
      • 7.2.2.1. Germany
      • 7.2.2.2. France
      • 7.2.2.3. Italy
      • 7.2.2.4. Spain
      • 7.2.2.5. United Kingdom
    • 7.2.3. Japan
  • 7.3. Total Cases of HSCT in the 7MM
  • 7.4. Total Cases of Kidney Transplant in the 7MM
  • 7.5. Total Cases of BKV Infection in the 7MM
  • 7.6. Total Cases of BK Viremia in Kidney Transplant Patients in the 7MM
  • 7.7. Total Cases of BKVAN in the 7MM
  • 7.8. Total Cases of BKHC in the 7MM
  • 7.9. The US
    • 7.9.1. Total Cases of BK Viremia in Kidney Transplant Patients in the US
    • 7.9.2. Total Cases of BKVAN in the US
    • 7.9.3. Classification-specific Cases of BKVAN in the US
    • 7.9.4. Type-specific HSCT Cases in the US
    • 7.9.5. Grade-specific Cases of BKHC in the US
  • 7.10. EU4 and the UK
    • 7.10.1. Total Cases of BK Viremia in Kidney Transplant Patients in EU4 and the UK
    • 7.10.2. Total Cases of BKVAN in EU4 and the UK
    • 7.10.3. Classification-specific Cases of BKVAN in EU4 and the UK
    • 7.10.4. Type-specific HSCT Cases in EU4 and the UK
    • 7.10.5. Total Cases of BKHC in EU4 and the UK
    • 7.10.6. Grade-specific Cases of BKHC in EU4 and the UK
  • 7.11. Japan
    • 7.11.1. Total Cases of BK Viremia in Kidney Transplant Patients in Japan
    • 7.11.2. Total Cases of BKVAN in Japan
    • 7.11.3. Classification-specific Cases of BKVAN in Japan
    • 7.11.4. Type-specific HSCT Cases in Japan
    • 7.11.5. Total Cases of BKHC in Japan
    • 7.11.6. Grade-specific Cases of BKHC in Japan

8. Patient Journey

9. Key Opinion Leaders' Views

10. Appendix

  • 10.1. Acronyms and Abbreviations
  • 10.2. Bibliography
  • 10.3. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Product Code: DIEI0498

List of Tables

  • Table 1: Summary of BKV Infection Epidemiology (2025-2036)
  • Table 2: BKV Screening Methods
  • Table 3: Recommendation monitoring schedule
  • Table 4: Diagnosis and monitoring
  • Table 5: Screening Methods for BKPyV-HC
  • Table 6: Grading systems used at ECIL-6 for levels of evidence and strength of recommendations
  • Table 7: Total Cases of HSCT in the 7MM (2022-2036)
  • Table 8: Total Cases of Kidney Transplant in the 7MM (2022-2036)
  • Table 9: Total Cases of BKV Infection in the 7MM (2022-2036)
  • Table 10: Total Cases of BK Viremia in Kidney Transplant Patients in the 7MM (2022-2036)
  • Table 11: Total Cases of BKVAN in the 7MM (2022-2036)
  • Table 12: Total Cases of BKHC in the 7MM (2022-2036)
  • Table 13: Total Cases of BK Viremia in Kidney Transplant Patients in the US (2022-2036)
  • Table 14: Total Cases of BKVAN in the US (2022-2036)
  • Table 15: Classification-specific Cases of BKVAN in the US (2022-2036)
  • Table 16: Type-specific HSCT Cases in the US (2022-2036)
  • Table 17: Total Cases of BKHC in the US (2022-2036)
  • Table 18: Grade-specific Cases of BKHC in the US (2022-2036)
  • Table 19: Total Cases of BK Viremia in Kidney Transplant Patients in EU4 and the UK (2022-2036)
  • Table 20: Total Cases of BKVAN in EU4 and the UK (2022-2036)
  • Table 21: Classification-specific Cases of BKVAN in EU4 and the UK (2022-2036)
  • Table 22: Type-specific HSCT Cases in EU4 and the UK (2022-2036)
  • Table 23: Total Cases of BKHC in EU4 and the UK (2022-2036)
  • Table 24: Grade specific cases of BKHC in EU4 and the UK (2022-2036)
  • Table 25: Total Cases of BK Viremia in Kidney Transplant Patients in Japan (2022-2036)
  • Table 26: Total Cases of BKVAN in Japan (2022-2036)
  • Table 27: Classification-specific Cases of BKVAN in Japan (2022-2036)
  • Table 28: Type-specific HSCT Cases in Japan (2022-2036)
  • Table 29: Total Cases of BKHC in Japan (2022-2036)
  • Table 30: Grade-specific Cases of BKHC in Japan (2022-2036)

List of Figures

  • Figure 1: Clinical Manifestations of BKV Infection
  • Figure 2: Sign and Symptoms of BKV Infection
  • Figure 3: Pathophysiology of BKV Infection
  • Figure 4: Diagnosis of BKV Infection
  • Figure 5: Diagnostic Algorithm of BKV Infection (Renal Transplantation)
  • Figure 6: Diagnostic Algorithm of BKV Infection
  • Figure 7: Total Cases of HSCT in the 7MM (2022-2036)
  • Figure 8: Total Cases of Kidney Transplant in the 7MM (2022-2036)
  • Figure 9: Total Cases of BKV Infection in the 7MM (2022-2036)
  • Figure 10: Total Cases of BK Viremia in Kidney Transplant Patients in the 7MM (2022-2036)
  • Figure 11: Total Cases of BKVAN in the 7MM (2022-2036)
  • Figure 12: Total Cases of BKHC in the 7MM (2022-2036)
  • Figure 13: Total Cases of BK Viremia in Kidney Transplant Patients in the US (2022-2036)
  • Figure 14: Total Cases of BKVAN in the US (2022-2036)
  • Figure 15: Classification-specific Cases of BKVAN in the US (2022-2036)
  • Figure 16: Type-specific HSCT Cases in the US (2022-2036)
  • Figure 17: Total Cases of BKHC in the US (2022-2036)
  • Figure 18: Grade-specific Cases of BKHC in the US (2022-2036)
  • Figure 19: Total Cases of BK Viremia in Kidney Transplant Patients in EU4 and the UK (2022-2036)
  • Figure 20: Total Cases of BKVAN in EU4 and the UK (2022-2036)
  • Figure 21: Classification-specific Cases of BKVAN in EU4 and the UK (2022-2036)
  • Figure 22: Type-specific Cases of HSCT in EU4 and the UK (2022-2036)
  • Figure 23: Total Cases of BKHC in EU4 and the UK (2022-2036)
  • Figure 24: Grade specific Cases of BKHC in EU4 and the UK (2022-2036)
  • Figure 25: Total Cases of BK Viremia in Kidney Transplant Patients in Japan (2022-2036)
  • Figure 26: Total Cases of BKVAN in Japan (2022-2036)
  • Figure 27: Classification-specific Cases of BKVAN in Japan (2022-2036)
  • Figure 28: Type-specific HSCT Cases in Japan (2022-2036)
  • Figure 29: Total Cases of BKHC in Japan (2022-2036)
  • Figure 30: Grade-specific Cases of BKHC in Japan (2022-2036)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!